Shigeru Tsuyuki1, Noriko Senda2, Yookija Kanng2, Ayane Yamaguchi3, Hiroshi Yoshibayashi4, Yuichiro Kikawa5,6, Nobuyuki Katakami7, Hironori Kato6, Takashi Hashimoto8, Toshitaka Okuno9, Akira Yamauchi10, Takashi Inamoto10,11. 1. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-8555, Japan. tyksgr@osaka-med.jrc.or.jp. 2. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-8555, Japan. 3. Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin, Sakyo-ku, Kyoto, Japan. 4. Department of Breast Surgery, Japanese Red Cross Society Wakayama Medical Center, 4-20, Komatsubara, Wakayama, Japan. 5. Department of Breast Surgery, Kobe City Medical Center West Hospital, 2-4, Ichiban-cho, Nagata-ku, Kobe, Japan. 6. Department of Breast Surgery, Kobe City Medical Center Central Hospital, 2-1-1, Minatojima, Minamimachi, Chuo-ku, Kobe, Japan. 7. Department of Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, 2-2, Minatojima Minamimachi, Chuo-ku, Kobe, Japan. 8. Hashimoto Clinic, 1-7-2, Sumimoto Honnmati, Nada-ku, Kobe, Japan. 9. Department of Breast Surgery, Nishi-Kobe Medical Center, 5-7-1, Kojidai, Nishi-ku, Kobe, Japan. 10. Department of Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20, Ohgimachi, Kita-ku, Osaka, Japan. 11. Department of Nursing Science, Tenri Health Care University, 80-1, Besho-cho, Tenri-city, Nara, Japan.
Abstract
PURPOSE: To investigate the efficacy of using surgical glove (SG) compression therapy to prevent nanoparticle albumin-bound paclitaxel (nab-PTX)-induced peripheral neuropathy. PATIENTS AND METHODS: Patients with primary and recurrent breast cancer who received 260 mg/m2 of nab-PTX were eligible for this case-control study. Patients wore two SGs of the same size, i.e., one size smaller than the size that fit their dominant hand, for only 90 min. They did not wear two SGs on the non-dominant hand, which served as the control hand. Peripheral neuropathy was evaluated at each treatment cycle using common terminology criteria for adverse events (CTCAE) version 4.0 and the Patient Neurotoxicity Questionnaire. The temperature of each fingertip of the compression SG-protected hand and control hand was measured using thermography. RESULTS: Between August 2013 and January 2016, 43 patients were enrolled and 42 were evaluated. The occurrence rates of CTCAE grade 2 or higher sensory and motor peripheral neuropathies were significantly lower for SG-protected hands than for control hands (sensory neuropathy 21.4 vs. 76.1 %; motor neuropathy 26.2 vs. 57.1 %). No patients withdrew from this study because they could not tolerate the compression from the SGs. SG compression therapy significantly decreased the temperature of each fingertip by 1.6-2.2 °C as compared with the temperature before chemotherapy (p < 0.0001). CONCLUSIONS: SG compression therapy is effective for reducing nab-PTX-induced peripheral neuropathy. The nab-PTX exposure to the peripheral nerve may be decreased because the SG decreases microvascular flow to the fingertip.
PURPOSE: To investigate the efficacy of using surgical glove (SG) compression therapy to prevent nanoparticle albumin-bound paclitaxel (nab-PTX)-induced peripheral neuropathy. PATIENTS AND METHODS: Patients with primary and recurrent breast cancer who received 260 mg/m2 of nab-PTX were eligible for this case-control study. Patients wore two SGs of the same size, i.e., one size smaller than the size that fit their dominant hand, for only 90 min. They did not wear two SGs on the non-dominant hand, which served as the control hand. Peripheral neuropathy was evaluated at each treatment cycle using common terminology criteria for adverse events (CTCAE) version 4.0 and the PatientNeurotoxicity Questionnaire. The temperature of each fingertip of the compression SG-protected hand and control hand was measured using thermography. RESULTS: Between August 2013 and January 2016, 43 patients were enrolled and 42 were evaluated. The occurrence rates of CTCAE grade 2 or higher sensory and motor peripheral neuropathies were significantly lower for SG-protected hands than for control hands (sensory neuropathy 21.4 vs. 76.1 %; motor neuropathy 26.2 vs. 57.1 %). No patients withdrew from this study because they could not tolerate the compression from the SGs. SG compression therapy significantly decreased the temperature of each fingertip by 1.6-2.2 °C as compared with the temperature before chemotherapy (p < 0.0001). CONCLUSIONS: SG compression therapy is effective for reducing nab-PTX-induced peripheral neuropathy. The nab-PTX exposure to the peripheral nerve may be decreased because the SG decreases microvascular flow to the fingertip.
Authors: Alexandre Chan; Amna Elsayed; Ding Quan Ng; Kathryn Ruddy; Charles Loprinzi; Maryam Lustberg Journal: Support Care Cancer Date: 2022-10-10 Impact factor: 3.359
Authors: Kathryn J Ruddy; Jennifer Le-Rademacher; Mario E Lacouture; Mary Wilkinson; Adedayo A Onitilo; Amy C Vander Woude; Maria T Grosse-Perdekamp; Travis Dockter; Angelina D Tan; Andreas Beutler; Charles L Loprinzi Journal: Breast Date: 2019-09-19 Impact factor: 4.380